Physician profile
Robert M Nadell
NPI 1801825344
$5,141.89
in general payments reported to CMS, 2019-2025
35 companies · $705 in 2025
The $705 reported for 2025 was more than what 87% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $814 · 2020: $331 · 2021: $906 · 2022: $867 · 2023: $788 · 2024: $732 · 2025: $705.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,225.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,225.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,075.27 | 2019-2025 | |
| Aspira Women'S Health INC | $566.87 | 2021-2023 | Ova1 |
| Celularity INC. | $320.00 | 2019 | |
| Mayne Pharma Commercial LLC | $317.64 | 2022-2025 | |
| Exeltis, USA INC. | $240.06 | 2019-2025 | Slynd |
| Evofem Biosciences, INC. | $225.60 | 2021-2025 | Phexxi, Solosec, Phexx |
| Avion Pharmaceuticals | $219.96 | 2020-2023 | Balcoltra |
| Pfizer INC. | $194.98 | 2019-2025 | |
| Hologic Sales and Service, LLC | $193.08 | 2019-2025 | Aptima, Myosure Tissue Removal Device, Fluent Fluid Management System |
| Organon LLC | $181.35 | 2021-2024 | Nexplanon |
| Therapeuticsmd, INC. | $177.74 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $168.34 | 2019-2025 | Gardasil 9, Gardasil |
| Agile Therapeutics, INC. | $152.18 | 2021-2024 | Twirla |
| Astellas Pharma US INC | $147.94 | 2023-2024 | Veozah |
| Biogen, INC. | $136.20 | 2024-2025 | Zurzuvae |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scynexis, INC. | $116.32 | 2022 | |
| Millicent US INC | $98.33 | 2023-2025 | Intrarosa, Femring |
| Lupin INC. | $88.06 | 2019-2021 | |
| Exact Sciences Corporation | $86.68 | 2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Allergan, INC. | $74.51 | 2019-2020 | |
| Shield Therapeutics INC | $71.69 | 2024-2025 | |
| Coopersurgical, INC. | $61.13 | 2021-2023 | Mara Console, Paragard T 380a |
| Amag Pharmaceuticals, INC. | $54.40 | 2019 | |
| Mission Pharmacal Company | $27.73 | 2020 | |
| Ge Healthcare | $22.19 | 2025 | |
| Sumitomo Pharma America, INC. | $18.95 | 2023 | Myfembree |
| Neos Therapeutics, LP | $17.06 | 2025 | Exxua |
| Duchesnay USA Incorporated | $14.99 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $14.46 | 2025 | |
| Myovant Sciences INC. | $13.64 | 2021 | |
| Pacira Pharmaceuticals Incorporated | $13.55 | 2021 | |
| Vertical Pharmaceuticals, LLC | $11.54 | 2019 | |
| Covidien LP | $11.20 | 2019 | |
| Channel Medsystems, INC. | $8.25 | 2023 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$5.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Nadell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.